(CCEL) CryoCell International - Ratings and Ratios

Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood and tissue for family use. The companys services include storing cord tissue, a rich source of mesenchymal stem cells, which are pivotal in regenerative medicine. These cells have potential applications in treating conditions such as heart and kidney diseases, ALS, and autoimmune disorders. Cryo-Cell manufactures the PrepaCyte CB system, a technology designed to process cord blood stem cells efficiently. The company markets its services directly to expectant parents and through healthcare professionals, enhancing its reach and accessibility. Established in 1989, Cryo-Cell is headquartered in Oldsmar, Florida, and is a notable player in the stem cell preservation industry.

From a technical standpoint, Cryo-Cells stock (CCEL) is currently trading at $7.12, slightly below its 20-day SMA of $7.61 and 50-day SMA of $7.42, but above the 200-day SMA of $7.15. This indicates a potential consolidation phase. The Average True Range (ATR) of 0.50 suggests low volatility, implying stable price movements. Fundamentally, with a market cap of $63.69M and a high P/B ratio of 9.72, the market anticipates significant growth. The RoE of 93.38 highlights efficient equity use, though the lack of profitability is reflected in the zero P/E ratio.

3-Month Forecast: Cryo-Cells stock is expected to remain in a sideways trend, supported by its 200-day SMA. The high P/B ratio and strong RoE suggest investor confidence in future growth, potentially driven by increasing demand for stem cell storage. However, the absence of current profitability may limit upside potential. The stock could see modest gains if the company demonstrates progress in partnerships or operational efficiency, otherwise, it may remain range-bound or experience slight decline.